

The logo for Seeking Alpha, with the text 'Seeking Alpha' in white and a gold Greek letter alpha symbol to the right, all on a dark red background.

DURECT Corporation Q1 2008 Earnings Call Transcript

Question-and-Answer Session

Operator

There is no question at this time

Matt Hogan

All right, let's wait one minute and see if anyone wants to ask a question, otherwise they can call us later.

Operator

Ken Trbovich with RBC Capital. I'll un-mute him now.

Matt Hogan

Okay.

Ken Trbovich - RBC Capital

Good afternoon, guys, can you hear me?

Jim Brown

Sure.

Ken Trbovich - RBC Capital

A quick question. At the panel meeting on Monday the issues that came out had to do with variability of the dose that can be extracted under different conditions for the Purdue formulation. Do you happen to know if Pain Therapeutics has conducted similar studies and whether or not there is similar variability for their formulation?

Jim Brown

We'll let the Remoxy product be defined and determined after the NDA has been filed as things go forward. Actually, some of the discussion was certainly more than just the part that you talked about, the variability. The only thing you can probably glean from what we've shown right now is we've shown some PK data from subjects who've been given Remoxy prepared in different ways versus OxyContin. You can look at that, that's in our corporate presentation. You'll see there a difference as

far as the amount of drug that can be extracted, as well I think we've shown some pictures of freeze fractured systems and things like that that Purdue didn't address at all.

Ken Trbovich - RBC Capital

Yeah, so the distinction would be that yours is actually in vitro data as opposed to some extrapolation that the panel and the agency were left to make on the Purdue formulation?

Jim Brown

I think that actually in vivo would have been the right.

Ken Trbovich - RBC Capital

In vivo, sorry about that. So a follow up question just with regard to the sufentanil program, you mentioned that management change at Endo has reinvigorated the program. I know you can't speak specifically to where things are at, but could you give us a sense of how the management changes in your view have been reinvigorated? What is it that gives you that confidence?

Jim Brown

I think we are just pleased to see that, we know Dave Holveck and his reputation, we know him from his time at J&J, he is a person who makes a difference wherever he goes, and is driven to accomplishment. He started to bring in his own team around him, a new head of R&D, and I know the day-to-day team on the Endo side is quite pleased with what's going on, as our team is here. And so I think we are just feeling a groundswell of continued force moving this thing forward.

Copyright © 2008 CNET Networks, Inc. All Rights Reserved.